Market Closed -
Saudi Arabian S.E.
08:20:04 2024-06-09 am EDT
|
5-day change
|
1st Jan Change
|
132.8
SAR
|
+1.07%
|
|
-0.15%
|
-3.07%
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
21,736
|
17,810
|
17,264
|
-
|
-
|
Enterprise Value (EV)
1 |
21,828
|
18,075
|
17,672
|
17,440
|
17,297
|
P/E ratio
|
24.5
x
|
19.9
x
|
20.6
x
|
18.4
x
|
17.3
x
|
Yield
|
-
|
4.01%
|
3.93%
|
4.36%
|
4.82%
|
Capitalization / Revenue
|
2.52
x
|
2.04
x
|
1.89
x
|
1.8
x
|
1.69
x
|
EV / Revenue
|
2.53
x
|
2.07
x
|
1.94
x
|
1.82
x
|
1.7
x
|
EV / EBITDA
|
13.6
x
|
11.5
x
|
11.3
x
|
10.3
x
|
9.71
x
|
EV / FCF
|
-
|
18.4
x
|
22.1
x
|
20
x
|
17.1
x
|
FCF Yield
|
-
|
5.45%
|
4.52%
|
5.01%
|
5.84%
|
Price to Book
|
9.69
x
|
7.92
x
|
6.76
x
|
6.35
x
|
6.1
x
|
Nbr of stocks (in thousands)
|
130,000
|
130,000
|
130,000
|
-
|
-
|
Reference price
2 |
167.2
|
137.0
|
132.8
|
132.8
|
132.8
|
Announcement Date
|
3/20/23
|
3/17/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
8,616
|
8,714
|
9,123
|
9,584
|
10,188
|
EBITDA
1 |
-
|
1,599
|
1,578
|
1,558
|
1,688
|
1,782
|
EBIT
1 |
-
|
1,003
|
961
|
896.4
|
999.2
|
1,069
|
Operating Margin
|
-
|
11.64%
|
11.03%
|
9.83%
|
10.43%
|
10.49%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
944.2
|
892
|
1,035
|
1,108
|
Net income
1 |
812.5
|
887.8
|
892.6
|
839.2
|
937.6
|
1,001
|
Net margin
|
-
|
10.3%
|
10.24%
|
9.2%
|
9.78%
|
9.83%
|
EPS
2 |
6.250
|
6.830
|
6.870
|
6.442
|
7.201
|
7.682
|
Free Cash Flow
1 |
-
|
-
|
984.2
|
798
|
873.3
|
1,011
|
FCF margin
|
-
|
-
|
11.3%
|
8.75%
|
9.11%
|
9.92%
|
FCF Conversion (EBITDA)
|
-
|
-
|
62.37%
|
51.2%
|
51.74%
|
56.73%
|
FCF Conversion (Net income)
|
-
|
-
|
110.26%
|
95.09%
|
93.14%
|
101%
|
Dividend per Share
2 |
-
|
-
|
5.500
|
5.222
|
5.792
|
6.407
|
Announcement Date
|
4/3/22
|
3/20/23
|
3/17/24
|
-
|
-
|
-
|
Fiscal Period: December |
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
---|
Net sales
1 |
-
|
2,239
|
2,159
|
2,138
|
2,105
|
-
|
2,163
|
2,214
|
2,258
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
305.8
|
278.5
|
153.9
|
263.2
|
-
|
229.8
|
215.1
|
231.6
|
Operating Margin
|
-
|
13.66%
|
12.9%
|
7.2%
|
12.51%
|
-
|
10.62%
|
9.71%
|
10.26%
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
1 |
237.5
|
268.5
|
253.8
|
128
|
-
|
265
|
-
|
-
|
232.9
|
Net margin
|
-
|
11.99%
|
11.76%
|
5.99%
|
-
|
-
|
-
|
-
|
10.32%
|
EPS
|
1.830
|
2.070
|
-
|
0.9900
|
-
|
2.040
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
5/23/22
|
8/11/22
|
11/3/22
|
3/20/23
|
5/11/23
|
8/3/23
|
11/5/23
|
3/17/24
|
5/8/24
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
91.8
|
265
|
408
|
176
|
33.4
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
0.0574
x
|
0.168
x
|
0.2617
x
|
0.1045
x
|
0.0188
x
|
Free Cash Flow
1 |
-
|
-
|
984
|
798
|
873
|
1,011
|
ROE (net income / shareholders' equity)
|
-
|
46.2%
|
37.9%
|
33.4%
|
35.9%
|
36.1%
|
ROA (Net income/ Total Assets)
|
-
|
19.2%
|
17.3%
|
15.3%
|
15.9%
|
16.1%
|
Assets
1 |
-
|
4,616
|
5,158
|
5,494
|
5,883
|
6,216
|
Book Value Per Share
2 |
-
|
17.30
|
17.30
|
19.60
|
20.90
|
21.80
|
Cash Flow per Share
2 |
-
|
12.80
|
10.50
|
10.10
|
10.40
|
9.070
|
Capex
1 |
-
|
275
|
385
|
423
|
371
|
374
|
Capex / Sales
|
-
|
3.19%
|
4.41%
|
4.64%
|
3.87%
|
3.67%
|
Announcement Date
|
4/3/22
|
3/20/23
|
3/17/24
|
-
|
-
|
-
|
Last Close Price
132.8
SAR Average target price
151.8
SAR Spread / Average Target +14.27% Consensus |
1st Jan change
|
Capi.
|
---|
| -3.07% | 4.6B | | -39.33% | 13.67B | | -8.96% | 7.95B | | +4.90% | 5.86B | | -14.16% | 5.71B | | +70.58% | 4.5B | | -8.29% | 3.77B | | -22.05% | 3.05B | | -12.94% | 2.81B | | -11.32% | 2.57B |
Other Drug Retailers
|